Marshall Wace North America L.P. Reduces Position in C.R. Bard, Inc. (BCR)

Marshall Wace North America L.P. cut its position in shares of C.R. Bard, Inc. (NYSE:BCR) by 85.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 74,773 shares of the medical instruments supplier’s stock after selling 455,597 shares during the period. Marshall Wace North America L.P. owned approximately 0.10% of C.R. Bard worth $23,629,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Whittier Trust Co. increased its position in shares of C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock worth $147,000 after buying an additional 42 shares in the last quarter. ClariVest Asset Management LLC purchased a new position in C.R. Bard during the first quarter worth approximately $148,000. SRS Capital Advisors Inc. increased its position in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 4 shares in the last quarter. Parallel Advisors LLC increased its position in C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 369 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. increased its position in C.R. Bard by 16.7% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 788 shares of the medical instruments supplier’s stock worth $196,000 after buying an additional 113 shares in the last quarter. Institutional investors own 77.14% of the company’s stock.

Shares of C.R. Bard, Inc. (NYSE:BCR) opened at 319.42 on Tuesday. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $323.27. The company has a market cap of $23.21 billion, a PE ratio of 41.94 and a beta of 0.59. The firm’s 50-day moving average price is $319.67 and its 200-day moving average price is $287.87.

C.R. Bard (NYSE:BCR) last released its earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.08. The business had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.54 earnings per share. Equities analysts predict that C.R. Bard, Inc. will post $11.82 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were paid a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio is currently 13.67%.

WARNING: This news story was originally published by [[site]] and is owned by of [[site]]. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at [[permalink]].

BCR has been the topic of a number of research reports. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective on the stock in a report on Tuesday, June 13th. BidaskClub downgraded C.R. Bard from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Morgan Stanley downgraded C.R. Bard from an “overweight” rating to an “equal weight” rating in a report on Monday, April 24th. Jefferies Group LLC increased their price objective on C.R. Bard from $237.00 to $317.00 and gave the stock a “hold” rating in a report on Monday, April 24th. Finally, BMO Capital Markets restated a “hold” rating and issued a $317.00 price objective on shares of C.R. Bard in a report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $285.67.

In other news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now owns 31,445 shares of the company’s stock, valued at $10,022,464.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.80% of the stock is owned by insiders.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.